Luspatercept
Reblozyl (luspatercept) is a protein pharmaceutical. Luspatercept was first approved as Reblozyl on 2019-11-08. It is used to treat anemia in the USA. It has been approved in Europe to treat anemia, beta-thalassemia, and myelodysplastic syndromes. It is known to target growth/differentiation factor 11, bone morphogenetic protein 10, growth/differentiation factor 2, growth/differentiation factor 8, and bone morphogenetic protein 6.
| Trade Name | Reblozyl |
|---|---|
| Common Name | Luspatercept |
| Indication | anemia, beta-thalassemia, myelodysplastic syndromes |
| Drug Class | Receptor molecules, native or modified: transforming growth factor |
